News

• Biogen revenue slips 6% to $2.53B in Q1
  05/03/2022 / 13:09 - TeleTrader
•  
• BIIB 10-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action
  03/29/2022 / 15:36 - GlobeNewswire
•  
• Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
  03/28/2022 / 13:30 - GlobeNewswire
•  
• Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ELMS, TAL, New Oriental, and Biogen and Encourages Investors to Contact the Firm
  03/28/2022 / 03:00 - GlobeNewswire
•  
• Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer
  03/22/2022 / 12:00 - GlobeNewswire
•  
• Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ELMS, TAL, New Oriental, and Biogen and Encourages Investors to Contact the Firm
  03/22/2022 / 02:00 - GlobeNewswire
•  
• SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims
  03/22/2022 / 00:16 - GlobeNewswire
•  
• Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors
  03/21/2022 / 12:05 - GlobeNewswire
•  
• Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Telos, Fennec, and Astra and Encourages Investors to Contact the Firm
  03/17/2022 / 02:00 - GlobeNewswire
•  
• Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease
  03/16/2022 / 16:54 - GlobeNewswire
•  
• Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
  03/15/2022 / 00:00 - GlobeNewswire
•  
• Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors
  03/14/2022 / 12:30 - GlobeNewswire
•  
• Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
  03/14/2022 / 12:30 - GlobeNewswire
•  
• SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
  03/13/2022 / 03:19 - GlobeNewswire
•  
• Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against New Oriental, Biogen, Telos, and Fennec and Encourages Investors to Contact the Firm
  03/12/2022 / 03:00 - GlobeNewswire